MedTrace Logo

Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD6234

NCT06845813 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-11-03

No results posted yet for this study

Summary

This study will evaluate the pharmacokinetics (PK), safety, and tolerability of single subcutaneous dose of AZD6234 with end stage renal disease, severe, and possibly moderate and mild renal impairment in comparison to a matched healthy control group.

Conditions

  • Renal Impairment

Interventions

DRUG

AZD6234

Dose 1

Sponsors & Collaborators

Principal Investigators

  • Fadi Saba, M.D. · Servico Integrado de Tecnicas Endovasculares

  • Thomas C Marbury, M.D. · Servico Integrado de Tecnicas Endovasculares

  • Joel M Neutel, M.D. · Servico Integrado de Tecnicas Endovasculares

  • Kwabena Ayesu, M.D. · Servico Integrado de Tecnicas Endovasculares

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-02-24
Primary Completion
2025-09-30
Completion
2025-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06845813 on ClinicalTrials.gov